The analysis showed that the mutation rate in ICC of TP53 was 27%, KRAS 22%, IDH 16%, and in EHC the mutation rate of TP53 was 40%, KRAS 42%, and SMAD4 21%. This evidence concerns the gene KRAS and intrahepatic cholangiocarcinoma.